{'fraction_non_alphanumeric': 0.026292725679228746, 'fraction_numerical': 0.04294478527607362, 'mean_word_length': 5.415730337078652, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interrelationship of serum S100B and P53 in brain tumour patients.

The interrelationship of serum S100B and P53 concentrations and their association with tumour type and size in patients was determined. S100B and P53 concentrations were measured in serum of patients and normal healthy volunteers. Serum S100B concentrations were significantly higher in patients (mean 50%) than in healthy controls (p< 0.001). P53 concentrations were elevated only in five patients (mean 28%). No significant correlation was found between S100B and P53. Significant positive correlation was observed between S100B concentration and large tumour size (p< 0.05) but not with small tumours. Similarly,there was no significant correlation between P53 concentrations and tumour size.Heterogeneity of S100B expression exists in brain tumours. However, S100B was also found to be pituitary-specific. High serum concentration of P53 was found in five patients with large tumour. These findings warrant further larger clinical studies for better understanding the interrelationship of these serum makers and the development and/or progression of these malignancies.